Dyadic国际 DYAI 深 沪
等待开盘 02-06 09:30:00 美东时间
0.8495
+0.002
+0.27%
华盛通- 最 高0.863
- 今 开0.8397
- 成交量 1.49万股
- 最 低 0.8251
- 昨 收 0.8472
- 总市值 3074.15万
- 52周最高 1.655
- 市盈率 静 --
- 换手率 0.04%
- 52周最低 0.711
- 委 比 98.76%
- 总股本 3618.78万
- 历史最高 10.98
- 量 比 0.29
- 振 幅 4.47%
- 历史最低 0.711
- 每 手 1
- 风险率 0.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Dyadic Applied Biosolutions Announced A Commercial Agreement With Opes Diagnostics To Support The Commercial Launch Of Dyadic's Recombinant Human Transferrin, Bovine Transferrin, Human FGF, And Bovine FGF Products For Use In Serum-free Cell Culture Media Applications
Under the agreement, Opes will leverage its existing commercial relationships and market experience to identify and engage potential customers primarily in Europe, Israel, and Asia to accelerate market entry for Dyadic's
2025-12-15 20:26
Market-Moving News for December 1st
QTTB: 97% | Q32 Bio Sells Phase 2 Complement Inhibitor ADX-097 To Akebia Therapeutics For $12M Upfront Payment; Co. Eligible To receive Up To $592M In Milestones As Well As Royalties DYAI: 35% | Dyadic
2025-12-01 20:37
Dyadic Applied BioSolutions And BRIG BIO Signs Development And Commercialization Agreement To Jointly Develop And Commercialize Recombinant Bovine Alpha-Lactalbumin
Dyadic Applied BioSolutions ("Dyadic"), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes across life science, food & nutrition, and bioindustrial markets, and BRIG BIO
2025-12-01 20:30
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
2025-11-12 19:11
Dyadic Applied BioSolutions, ERS Genomics Signs Agreement To Grant Dyadic Access To ERS' CRISPR/Cas9 Patent Portfolio
ERS Genomics Limited (‘ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial
2025-11-10 20:28
Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics
ERS Genomics and Dyadic Applied BioSolutions have signed a CRISPR/Cas9 license agreement, granting Dyadic access to ERS' CRISPR/Cas9 patent portfolio to enhance strain engineering and pathway optimization across its bioproduction platforms, benefiting life sciences, food and bio-industrial sectors. This collaboration underscores the utility of CRISPR technology in driving efficiency and innovation.
2025-11-10 12:25
美股大行评级 | 上调目标价！特斯拉、赛默飞世尔、拉姆研究、波士顿科学、安诺电子、金沙集团等获众多机构评级
今日重点评级关注：摩根士丹利：维持Viking Therapeutics"超配"评级，目标价从98美元升至102美元；摩根大通：维持IDEAYA Biosciences"超配"评级，目标价从74美元升至79美元
2025-10-24 09:51
HC Wainwright & Co. Assumes Dyadic International at Buy, Announces Price Target of $3
HC Wainwright & Co. analyst Swayampakula Ramakanth assumes Dyadic International (NASDAQ:DYAI) with a Buy rating and announces Price Target of $3.
2025-10-23 18:41
Dyadic International Achieves Milestone Payments and Compliance
The latest update is out from Dyadic International ( ($DYAI) ). On October 6, 2...
2025-10-08 04:55
Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments
Dyadic Applied BioSolutions reported Q3 2025 milestones, including $500,000 for Proliant partnership and $250,000 from Inzymes collaboration. Key advancements in recombinant proteins for life sciences and food nutrition include commercial launches targeted for late 2025 and early 2026, along with expanded sampling and production activities. The company is transitioning to a commercially focused strategy, capitalizing on its diverse product pipeli...
2025-10-06 12:30
